- AU$14.64m
- AU$15.95m
- AU$14.61m
Brief: ImpediMed Announces Management Reorganisation
Brief: ImpediMed Extends Contract For AstraZeneca For Use Of The SOZO Digital Health Platform In Clinical Trial Of Patients With Chronic Kidney Disease
Brief: Impedimed Says AstraZeneca Further Extends Clinical Trial Contract
Brief: Impedimed Ltd Says Current Data Support Early Detection And Intervention To Reduce Rates Of Breast Cancer-Related Lymphedema
Brief: Impedimed Ltd Says Signs A Global Strategic Commercial Partnership And Pilot Program
Australia's ImpediMed soars on tie-up to provide breast cancer screening services
Australia's ImpediMed hits one-month low after posting annual loss
Brief: Impedimed Says FY Net Loss Attributable A$19.9 Million
Brief: Impedimed Says CEO Announces Departure
Australia's ImpediMed rises on extending contract with AstraZeneca
Brief: Impedimed Says Second Contract Extension Its Sozo Digital Health Platform For Astrazeneca
Australia Stock Exchange release from IMPEDIMED : PRE_NR Ends: 10:34:31
Australia Stock Exchange release from IMPEDIMED : AstraZeneca extends and increases Renal Contract
Australia Stock Exchange release from IMPEDIMED : Bone Data Presented, Strong Correlation between SOZO and DXA
Australia Stock Exchange release from IMPEDIMED : S&P DJI Announces March 2022 Quarterly Rebalance
Australia Stock Exchange release from IMPEDIMED : PRE_NR Ends: 17:13:11
Brief: Impedimed Ltd Posts HY Net Loss Attributable A$8.9 Million
Australia Stock Exchange release from IMPEDIMED : PRE_NR Ends: 08:15:16
Australia Stock Exchange release from IMPEDIMED : Appendix 4D and Interim Financial Report